Most Popular
-
1
Dongduk Women’s University halts coeducation talks
-
2
Defense ministry denies special treatment for BTS’ V amid phone use allegations
-
3
Russia sent 'anti-air' missiles to Pyongyang, Yoon's aide says
-
4
OpenAI in talks with Samsung to power AI features, report says
-
5
Two jailed for forcing disabled teens into prostitution
-
6
Trump picks ex-N. Korea policy official as his principal deputy national security adviser
-
7
South Korean military plans to launch new division for future warfare
-
8
Gold bars and cash bundles; authorities confiscate millions from tax dodgers
-
9
Kia EV9 GT marks world debut at LA Motor Show
-
10
Teen smoking, drinking decline, while mental health, dietary habits worsen
[DISCLOSURE] Jeil Pharmaceutical (002620) announced on Sept. 8 that it will spin off its non-prescription medicine business division.
The new company, Jeil Health Science, will be devoted to developing new over-the-counter drugs.
Jeil Pharmaceutical will remain a public company and continue managing prescription medicine brands. The due date is Nov. 11.
By Yun Jeong-hyeon (clareyun@heraldcorp.com)
The new company, Jeil Health Science, will be devoted to developing new over-the-counter drugs.
Jeil Pharmaceutical will remain a public company and continue managing prescription medicine brands. The due date is Nov. 11.
By Yun Jeong-hyeon (clareyun@heraldcorp.com)
